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he “Vulnerable” Stent
hy So Dreadful?*
ernando Alfonso, MD, PHD, FESC
adrid, Spain
n a new era where the clinical manifestations of acute
oronary syndromes are just considered to be the peak of the
ceberg of an underlying systemic inflammatory process,
erms such as “vulnerable plaque” have lost appeal in favor of
ore comprehensive terminology such as vulnerable blood,
ulnerable myocardium, and vulnerable patient (1). Ulti-
ately, all of them emphasize the need for implementing
lobal preventive therapeutic strategies in the management
f these patients.
See page 2396
Coronary interventions, however, are increasingly being
sed in unstable patients, and stent implantation is currently
onsidered the best possible intervention to effectively tackle
iscrete coronary lesions. In this scenario, drug-eluting
tents (DES) emerged and quickly revolutionized the field
f interventional cardiology. As compared with bare-metal
tents (BMS), DES are able to dramatically reduce neoin-
imal proliferation and restenosis rate, leading to a major
eduction in the need for target vessel revascularization and
n improved long-term clinical outcome (2,3). Drug-eluting
tents, however, have been unable to reduce the incidence of
tent thrombosis. Their potent anti-inflammatory and an-
iproliferative properties might, in fact, constitute a double-
dged sword, delaying endothelization and promoting vessel
emodeling and late acquired malapposition that, in turn,
ight favor stent thrombosis (4). We need to acknowledge
hat the concern that DES could be more vulnerable to
hrombosis than BMS has always been there and, in fact,
rom their early implementation prolonged dual antiplatelet
egimens were systematically recommended in these pa-
ients. In addition, some controversial and provocative
reliminary studies suggested that DES might be associated
ith a poorer clinical outcome, likely as the result of an
ncreased risk of stent thrombosis (5,6). For a while, it was
ifficult to differentiate the fire from the smoke, and the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From Interventional Cardiology, Cardiac Department, Cardiovascular Institute,
an Carlos University Hospital, Madrid, Spain.omplete field of coronary revascularization was temporarily
estabilized. Definitions of stent thrombosis were revisited,
nd new recommendations were issued regarding extended
1 year) dual antiplatelet regimens.
Fortunately, subsequent systematic and exhaustive scru-
iny of all pivotal randomized clinical trials (using patient-
evel data from the raw databases and independent analyses)
ailed to identify any potential increased risk for major
dverse cardiac events (death and myocardial infarction)
ssociated with the use of DES (2,3). Later on, additional
ell-designed analyses of large “real world” registries, where
ES were often implanted for “off label” indications,
onfirmed the long-term clinical safety of DES and, in some
ases, even their superior safety profile compared with BMS
7,8). Eventually, after the storm the calm prevailed, and it
s expected that all of these reassuring data will generate a
econd wind effect in the clinical use of these new devices,
efueling their market penetration.
In all of these analyses, however, a clear distinct temporal
attern of stent thrombosis emerged: whereas most episodes
f BMS thrombosis clustered early after the procedure, the
istribution of DES thrombosis was relatively late skewed
ith a certainly small but sizeable number of episodes
ccurring very late (1 year) (9). Moreover, we still do not
now how to reconcile some conflicting findings stemming
rom these studies, namely the risk for very late DES
hrombosis (up to 0.6% annually in some reports) (9) and
he unaffected myocardial infarction and mortality rates
2,3). This apparent paradox is particularly striking consid-
ring the adverse clinical outcome experienced by most
atients suffering this complication (10–14). Could it be
hat the slight increase in the incidence of late thrombosis
ould require larger series of patients or much longer
eriods of follow-up to be clinically recognizable? Alterna-
ively, a more optimistic explanation would be that the
educed need of repeated revascularization obtained with
ES might eventually pay off, because restenosis (formerly
resented as an innocent nuisance) could actually be asso-
iated with a marginal risk of untoward clinical events.
Currently, the dilemma might be summarized as follows:
ither we choose DES to overcome the risk of restenosis
still the Achilles’ heel of BMS) or rather we select BMS to
void the long shadow cast by the fear of very late stent
hrombosis (still the Damocles sword of DES). Because of
he major implications in clinical decision making of this yet
nsolved dilemma, it is quite surprising that the term
vulnerable stent” has not yet gained widespread acceptance.
an we identify clinical and anatomic factors increasing
tent vulnerability? Should we consider all DES as “vulner-
ble” stents? Should we obtain more in vitro or in vivo
nsights to confirm adequate platelet inhibition in patients
ith vulnerable stents? Why should we keep struggling to
dentify vulnerable plaques, if eventually our stents are also
ulnerable? Finally, why is the prognosis of stent thrombosis
o dismal despite timely and adequate management? This
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Editorial Comment June 24, 2008:2403–6atter question is beautifully addressed in an elegant piece of
ork reported in this issue of the Journal (15).
he “Vulnerable” Stent
able 1 summarizes clinical, procedural, anatomic, and
iological factors associated with the risk of stent thrombo-
is (10–14). Most of these factors apply both to BMS and
ES. Mechanical factors are clearly implicated in the
athophysiology of vulnerable stents (10–14). Patients suf-
ering from BMS thrombosis frequently present underex-
anded stents, significant inflow/outflow disease, uncovered
issections, and incomplete stent apposition (10). The same
echanical factors seem to play a major role in patients
uffering DES thrombosis (11). In addition, the profound
bility of DES to inhibit neointimal proliferation seems to
e closely linked with a delayed process of endothelization,
t least with the first generations of these devices. Patho-
ogic, angioscopic, and optical coherence tomography stud-
es have clearly demonstrated that DES, in contradistinction
ith BMS, might remain incompletely endothelized after 6
onths, and this finding has been related to fibrin deposi-
ulnerable Stents
Table 1 Vulnerable Stents
Clinical factors
Early discontinuation of antiplatelet therapy
Acute coronary syndrome/acute myocardial infarction
Diabetes
Renal failure
Depressed left ventricular function
Anatomical factors
Angiographic
Thrombus laden lesions
Bifurcations
In-stent restenosis
Long multiple stents/lesions
Small vessels
Suboptimal results/residual dissections
Intravascular ultrasound
Stent underexpansion
Inflow/outflow disease
Residual dissections
Stent malapposition
Aneurysms
Angioscopy/optical coherence tomography
Lack of endothelization
Stent malapposition
Biological factors
Delayed reendothelization
Endothelial dysfunction
Vessel remodeling
Tissue factor expression
Resistance to aspirin/clopidogrel
Chronic inflammation
Hypersensitivity reactions
Genetic polymorphisms
Thrombophiliaion and stent thrombosis (4). Furthermore, in DES the iolymer might occasionally elicit inflammatory and allergic
eactions that favor DES thrombosis (4). Finally, these
ioactive stents might alter the normal healing process of
he vessel wall and also trigger positive vessel remodeling
eading to acquired malapposition. Indeed, this finding is
ore frequently found after DES than after BMS implan-
ation. We should keep in mind, however, that suboptimal
tent deployment and even malapposition is relatively com-
on but, fortunately enough, stent thrombosis remains very
are. However, the other side of the same coin is also of
nterest, and different studies have demonstrated that un-
erexpansion and malapposition are frequently detected in
atients suffering stent thrombosis (10,11). Which face of
anus is telling the truth? Is there any important information
issing in the equation?
The previous discussion leads us to speculate that—
imilar to the pathophysiology of many arrhythmias—3
omplementary and potentially interrelated factors should
e considered in patients suffering from stent thrombosis.
hese 3 key factors would include: 1) a predisposing
nderlying anatomic substrate (i.e., stent underexpansion,
alapposition, subtle mechanical problems, incomplete en-
othelization); 2) an unfavorable thrombogenic milieu (i.e.,
rug discontinuation, resistance to aspirin or clopidogrel,
enetic polymorphisms, thrombophilia, rheologic problems);
nd 3) the trigger (i.e., any potent stimulus for platelet
ctivation). We propose that these 3 aspects comprising the
vulnerability triangle” should be systematically investigated
nd eventually corrected in all patients experiencing stent
hrombosis.
onsequences of Stent Thrombosis
hy is stent thrombosis so dreadful? One would be
empted to anticipate that episodes of stent thrombosis
ould have a better—or at least a similar—clinical outcome
han that seen in the general population of patients treated
ith primary angioplasty. Although most of these stents are
mplanted in relatively large proximal vessels, the same is
rue for most patients presenting with ST-segment eleva-
ion myocardial infarction. Episodes of stent thrombosis are
elatively easy to identify, potentially leading to an early
reatment. In fact, many of them occur when the patient is
till in the hospital and can be expeditiously treated. These
atients should readily recognize their symptoms, and per-
onnel at the emergency department should quickly suspect
he diagnosis and forward the patient for urgent cardiac
atheterization. Finally, before reintervention, coronary anat-
my might be carefully reviewed to anticipate any difficulties
nd also to select the most appropriate strategy to optimize
esults. Paradoxically, however, most studies suggest that,
espite early and aggressive management, episodes of DES
hrombosis are systematically associated not only with large
-wave myocardial infarctions but also with a higher-than-
xpected mortality rate (12,13). In an early study (13),
n-hospital and 9-month mortality rates were 24% and 45%,
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June 24, 2008:2403–6 Editorial Commentespectively. This is, by far, higher than that seen in patients
ith ST-segment elevation myocardial infarction caused by
e novo lesions. However, selection biases might help to
xplain some of these previous findings.
In this issue of the Journal, Chechi et al. (15) sought to
nravel the reasons explaining why stent thrombosis is
ssociated with such an adverse prognosis. Clinical and
ngiographic results of primary angioplasty in these
atients were thoroughly compared with those seen after
onventional primary angioplasty procedures. Eighty-six
atients treated for definitive stent thrombosis (64% early
hrombosis, 72% DES) were retrospectively compared
ith 98 consecutive patients with ST-segment elevation
yocardial infarction treated for “de novo” lesions. Be-
ause patients with stent thrombosis had more adverse
aseline characteristics, logistic regression analyses (with
ropensity-adjustment) were performed to account for
onfounders. Time to intervention was similar in both
roups. Notably, however, a significantly large angio-
raphic thrombus burden was identified in the cohort of
atients with stent thrombosis. Successful reperfusion—
he primary outcome measure—was significantly lower,
nd in-hospital mortality was significantly higher in these
atients. After adjustment, stent thrombosis emerged as
n independent predictor of unsuccessful coronary reper-
usion. In addition, the cumulative rate of major adverse
ardiac events at 6 months was significantly higher in
atients with stent thrombosis, although these differences
isappeared after adjustment. Stent type was not related
o prognosis, but specific analyses to identify predictors of
dverse outcome in this setting were not performed. The
uthors eventually concluded that management strategies
hould be improved in these patients (15).
The in-hospital mortality rate of this series was 17.4%,
hich favorably compares with initial reports of patients
reated for stent thrombosis but is in line with the results of
ore recent studies (10–12,14). Interestingly enough, de-
pite the larger thrombus burden detected in patients with
tent thrombosis, the use of adjunctive antiplatelet medica-
ions and thrombus removal devices was similar to that seen
n the control group. This could explain the lower rate of
dequate reperfusion and the higher rate of distal emboli-
ation detected in the stent thrombosis group. Moreover,
fter intervention the residual angiographic stenosis was
ore severe in patients with stent thrombosis (final minimal
umen diameter of only 2  0.7 mm). Maximal inflation
ressures were not reported, but it is likely that residual
hrombus rather than underexpanded stents would account
or these poorer angiographic results. In 2 previous prospec-
ive intravascular ultrasound studies we demonstrated that,
espite all optimization efforts (aggressive balloon dilation
nd stents for residual dissections, together with a system-
tic use of glycoprotein IIb/IIIa platelet inhibitors, throm-
ectomy devices, and intravascular ultrasound-guided stent
ptimization), a significant amount of “resistant” thrombus
s consistently visualized after the procedure in patients
Mreated for either BMS or DES thrombosis (10,11). These
ndings could help to explain the suboptimal angiographic
ndings found by Chechi et al. (15) at the epicardial vessel
evel, which together with the severe derangement of the
icrovascular bed would jeopardize the results of these rescue
rocedures. In contrast, whether thrombus in patients with
tent thrombosis is not only larger but also qualitatively
ifferent (i.e., more resistant to mechanical and pharmacolog-
cal interventions) than that encountered during standard
rimary angioplasty procedures remains to be elucidated.
Treatment of patients suffering episodes of stent throm-
osis constitutes not only a medical emergency but also a
niquely challenging procedure. Currently, no information
xists regarding the best interventional strategy for this
ntity, and most recommendations remain empirical. Fur-
hermore, individual responses of intracoronary thrombi to
nterventions remain unpredictable (16). However, owing to
he catastrophic clinical consequences potentially associated
ith this complication, we believe that particularly aggres-
ive measures are clearly warranted. First of all, mechanical
ow restoration should be achieved immediately. Then,
otent adjuvant antiplatelet and antithrombotic drugs, to-
ether with thrombus aspiration devices, should be system-
tically used, owing to the large amount of thrombus
ccluding the stent. Furthermore, intravascular ultrasound
uidance should be indicated to tackle any potential me-
hanical predisposing factor and to guarantee stent optimi-
ation (10,11). Lastly, ensuring the long-term maintenance
f a dual antiplatelet regimen might not be sufficient in
hese patients, because many of them are indeed resistant to
hese medications. Detailed studies of platelet reactivity,
onfirming adequate platelet inhibition under the selected
ntiplatelet regimen, could be of paramount importance in
hese patients who are at very high risk for recurrences (17).
his is of special interest in light of recent information
uggesting that larger maintenance doses or even new
ntiplatelet agents might be particularly effective in selected
igh-risk patients (17).
Further studies are urgently required to improve stent
election according to the clinical and anatomic setting,
o optimize deployment techniques, to better identify
ulnerable stents, and last but not least, to elucidate the
est antiplatelet regimen and its duration to prevent stent
hrombosis. In patients suffering from this dreadful compli-
ation, improved interventional strategies should be devel-
ped to ensure optimal results after these challenging
rocedures. Hopefully, next-generation stents will be able to
educe the rate of restenosis even further while, at the same
ime, completely abolishing the risk of thrombosis. Only
hen will “vulnerable stents” no longer be an issue.
eprint requests and correspondence: Dr. Fernando Alfonso,
nterventional Cardiology, Cardiac Department, Cardiovascular
nstitute, San Carlos University Hospital, Plaza de Cristo Rey,
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